会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
    • 细胞可渗透的Nm23重组蛋白,编码它们的多核苷酸和包含其的抗转移组合物
    • US08450279B2
    • 2013-05-28
    • US12676182
    • 2008-09-04
    • Daewoong JoThi Thuy Nga DoKisuk Park
    • Daewoong JoThi Thuy Nga DoKisuk Park
    • C12N15/12
    • C12N9/12A61K38/1709C07K2319/00C07K2319/09C07K2319/10
    • The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells.
    • 本发明公开了一种细胞渗透性的Nm23重组蛋白,其中大分子转导结构域(MTD)与转移抑制基因Nm23融合。 还公开了编码细胞可渗透性的Nm23重组蛋白质的多核苷酸,含有细胞可渗透性的Nm23重组蛋白质的表达载体,以及含有细胞可渗透性的Nm23重组蛋白质作为有效成分的用于预防转移的药物组合物。 本发明的细胞可渗透的Nm23重组蛋白可以通过有效地将转移抑制基因Nm23引入细胞来诱导KSR磷酸化和失活并抑制Ras介导的MAPK级联。 因此,通过抑制癌细胞的增殖,分化和迁移,本发明的细胞可渗透的Nm23重组蛋白可以有效地用作能够预防癌转移的抗转移剂。
    • 3. 发明授权
    • Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same
    • 细胞可渗透性p18重组蛋白,编码其的多核苷酸和包含其的抗癌组合物
    • US08445443B2
    • 2013-05-21
    • US12676491
    • 2008-09-04
    • Daewoong JoSeolhwa KimJung-Hee LimKisuk ParkSe-Eun Kang
    • Daewoong JoSeolhwa KimJung-Hee LimKisuk ParkSe-Eun Kang
    • C12N15/62
    • C07K14/4703C07K14/50C07K2319/033
    • The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent.
    • 本发明公开了一种细胞渗透性p18重组蛋白,其中大分子转导结构域(MTD)与肿瘤抑制基因p18融合。 还公开了编码细胞可渗透性p18重组蛋白质的多核苷酸,含有细胞可渗透性p18重组蛋白质的表达载体和含有细胞可渗透性p18重组蛋白质作为有效成分的p18缺陷或失败的药物组合物。 本发明的细胞可渗透性p18重组蛋白能够有效地将不充分的单倍体肿瘤抑制基因p18引入细胞,从而可以激活参与ATM和p53激活的细胞信号传导机制,诱导细胞周期停滞和凋亡,以响应于 DNA损伤或致癌信号。 因此,本发明的细胞可渗透性p18重组蛋白质可以有效地用作抗癌剂。